Search
Ceftibuten
go.drugbank.com/drugs/DB01415ApprovedInvestigationalIt is typically used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.
Indoramin
go.drugbank.com/drugs/DB08950ApprovedWithdrawnIt is a selective alpha-1 adrenergic antagonist with no reflex tachycardia and direct myocardial depression action.
Iodide
go.drugbank.com/drugs/DB12754ApprovedInvestigationalWithdrawnIodide has been investigated for the treatment of Goiter, Nodular.
VP025
go.drugbank.com/drugs/DB05133ExperimentalIt is considered to be a systemic anti-inflammatory and neuroprotective agent. … It also shows the ability to reduce inflammation across the blood-brain barrier and improve correlates of memory and learning function.
Alethine
go.drugbank.com/drugs/DB05800InvestigationalIt belongs to a family of chemicals called disulfides. It is a low molecular weight disulfide that has been shown to exhibit in vivo antitumor activity in murine myeloma and melanoma models.
International brands: Beta LTBombesin
go.drugbank.com/drugs/DB11724InvestigationalBombesin is under investigation in clinical trial NCT01205321 (PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86
Mycobacterium w. Vaccine
go.drugbank.com/drugs/DB15798InvestigationalIt has protective efficacy against M. tuberculosis and M. leprae. As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials. … As an immunotherapy, M.w is used against leprosy; the compound also shares antigens with M. tuberculosis.
Thymectacin
go.drugbank.com/drugs/DB05116InvestigationalThymectacin, a phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine, is a novel small molecule anticancer agent. … Thymectacin was as efficacious as irinotecan, a drug recently approved for the treatment of 5-fluorouracil-resistant colon cancer.
MBP134
go.drugbank.com/drugs/DB18686ExperimentalMBP134 is a pan-ebolavirus cocktail comprising two broadly neutralizing human antibodies. It is under investigation for the treatment of Sudan ebolavirus (SUDV).